
Germany’s Aicuris revealed it has entered into a definitive agreement under which Asahi Kasei (TYO: 3407), through its wholly owned US subsidiary Veloxis Pharmaceuticals, acquire all shares of Aicuris for a total of 780 million euros (~$920 million).
The acquisition will enable Asahi Kasei to strategically expand its portfolio of therapies designed to treat severe viral infections, addressing critical infectious complications faced by patients undergoing hematopoietic stem cell transplant, solid organ transplants and other immunologically driven conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze